City Therapeutics stock: Price History and Returns
CTYCity Therapeutics's share price fell by 2.6% a year over the last 10 years, 23.3% in total. City Therapeutics does not pay a dividend at present, so the return came from the share price alone.
This shows what City Therapeutics Inc. has returned on the stock market in the past. Past returns say nothing about the future.
Daily figure as of 20 Nov 2026
Share Price Since 2013
How City Therapeutics Has Performed
The stock has not yet recovered its largest drawdown of 51.8% between August 2016 and March 2020 and trades 29.3% below the high today. From 2016 to 2018 the stock fell three years in a row. 3 of 7 full calendar years since 2014 ended with a loss. The best year was 2019 at +37.8%, the weakest 2018 at −18.2%.
Since the start of the year the stock is down 26.7%. At +1%, 2020 was close to the 10-year average of −2.6% a year.
How City Therapeutics Compares
Over 10 years City Therapeutics trailed the S&P 500: −2.6% a year against +14.3% for the index, in US dollars.
| Period | City Therapeutics | S&P 500 |
|---|---|---|
| 1 year | −26.7% | +114.9% |
| 5 years | −6% | +16.5% |
| 10 years | −2.6% | +14.3% |
Returns of Industry Peers
Among its industry peers, Vor Biopharma led over one year (+136.8%) and Structure Therapeutics trailed furthest (−53.1%).
| Stock | 1 year | 5 years |
|---|---|---|
| Vor Biopharma | +136.8% | −93.2% |
| Structure Therapeutics | −53.1% | no data |
| Solid Biosciences | +43.8% | −78.4% |
| Inventiva | −8.4% | −72.5% |
| MoonLake Immunotherapeutics | −18.5% | +11.2% |
What Became of $1,000
Of $1,000 invested in City Therapeutics 10 years ago, $767 is left today.
With dividends means each dividend is reinvested at the closing price on the ex-date, before taxes and costs. The index is represented by an accumulating ETF, dollar amounts at ECB rates. Industry figures are share price returns only, in each exchange's currency, as of 20 Nov 2026.
Returns by Period
| Period | Total | Per year |
|---|---|---|
| 1 year | −26.7% | −26.7% |
| 3 years | −26.7% | −9.9% |
| 5 years | −26.7% | −6% |
| 10 years | −23.3% | −2.6% |
| Since 2013 | −26.5% | −2.3% |
Returns by Calendar Year
Figures as a table
| Year | Closing price | Return |
|---|---|---|
| 2026 to date | $18.35 | −26.7% |
| 2020 | $25.05 | +1% |
| 2019 | $24.80 | +37.8% |
| 2018 | $18.00 | −18.2% |
| 2017 | $22.00 | −3% |
| 2016 | $22.69 | −8.7% |
| 2015 | $24.84 | +3.1% |
| 2014 | $24.10 | +27.2% |
Peak Price and Largest Drawdown
This is the pure share price return in US dollars from closing prices, adjusted for stock splits. Dividends come on top and are not included here.
Work out your own amount and period in the What-if calculatorData and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2019. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
